From the Journals

Bimekizumab in Psoriasis: 3-Year Outcomes

Investigators compare patient-reported symptoms and quality-of-life outcomes vs secukinumab.

Share

  • 1

    BE RADIANT trial involved 743 patients with moderate to severe plaque psoriasis.

  • 2

    Bimekizumab (320 mg) showed superior results compared to secukinumab (300 mg).

  • 3

    Improvements were seen as early as week 4 and sustained to 3 years.

  • 4

    Patient-reported outcomes were measured using specific instruments.

  • 5

    Quality of life assessed via Dermatology Life Quality Index.

  • 6

    Large sample size and low dropout rate noted as strengths.

  • 7

    Limitations include eligibility criteria affecting generalizability.

Original Source(s)

Bimekizumab in Psoriasis: 3-Year Outcomes

Investigators compare patient-reported symptoms and quality-of-life outcomes vs secukinumab.

  • by Kathryn Wighton

  • March 12, 2026

  • 5 min

Related Content

What Prevents Chemo-Linked HFS?

Network meta-analysis compares preventive agents for chemotherapy-induced hand-foot syndrome

Ivermectin vs Permethrin for Scabies

Investigators evaluate household-level cure rates in dermoscopy-confirmed cases at day 28.

Bad Hair Day

Non-targeted mass spectrometry finds chemicals linked to cancer and hormone disruption in hair extensions 

  • March 3, 2026

  • 2 min